Key facts
- APIX Biosciences’s last known valuation is $88.5M (Jul 2025).
- It has raised $31.3M.
- Notable investors include Hebrew University of Jerusalem Endowment, Newcastle University, University of Pretoria, Yissum.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for APIX Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for APIX Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About APIX Biosciences
Manufacturer of animal feed products intended to focus on the sustainability of apiculture, pollination, and agriculture, and protecting biodiversity. The company specializes in feed formulations to support honeybee colonies and reduce mortality rates within hives and strengthens colonies, particularly during challenging pollination events and stressful periods such as transportation, drought, pollen scarcity, harsh weather conditions, and exposure to pesticides, helping beekeepers, growers, and society by transforming the way bees and pollination are managed and strengthening the global food supply system.
- Sector
- Materials and Resources
- HQ
- Wingene, Belgium
- Founded
- 2017
- Employees
- 4
- Website
- apixbiosciences.com/
- Ownership
- Privately Held (backing)
APIX Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in APIX Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on APIX Biosciences in its N-PORT filings yet. We sweep new filings monthly.